(Q39456735)

12 September 2017

title

Targeting the Microenvironment in Advanced Colorectal Cancer (English)

1 reference

12 September 2017

1 reference

Daniele V. F. Tauriello

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28741478%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Eduard Batlle

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28741478%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Daniele V F Tauriello

series ordinal

1

1 reference

12 September 2017

language of work or name

1 reference

21 August 2016

1 reference

12 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28741478%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28741478%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28741478%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

495-504

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28741478%20AND%20SRC:MED&resulttype=core&format=json

A genetic model for colorectal tumorigenesis

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Molecular genetics of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The genomic landscape of response to EGFR blockade in colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Classification of colorectal cancer based on correlation of clinical, morphological and molecular features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

A colorectal cancer classification system that associates cellular phenotype and responses to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The consensus molecular subtypes of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The basics of epithelial-mesenchymal transition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Stromal contribution to the colorectal cancer transcriptome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The distribution of secondary growths in cancer of the breast. 1889

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Microenvironmental control of stem cell fate in intestinal homeostasis and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Microenvironmental regulation of stem cells in intestinal homeostasis and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Drug resistance and the solid tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Microenvironmental regulation of therapeutic response in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Targeting the tumor microenvironment: from understanding pathways to effective clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Microenvironmental regulation of tumor progression and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Accessories to the crime: functions of cells recruited to the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Co-evolution of tumor cells and their microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Influence of tumour micro-environment heterogeneity on therapeutic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Cancer as an evolutionary and ecological process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Turning ecology and evolution against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The tumor microenvironment in colorectal carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The gastrointestinal tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Molecular mechanisms and clinical applications of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Metronomic chemotherapy: new rationale for new directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

TGF-beta in CAF-mediated tumor growth and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

TGFβ signaling plays a critical role in promoting alternative macrophage activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The roles of TGFβ in the tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Targeting the TGFβ signalling pathway in disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Targeting the TGFβ pathway for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Molecular pathways: targeting the TGF-β pathway for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

SMAD4 as a Prognostic Marker in Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Isolation and in vitro expansion of human colonic stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Patient-derived tumor xenografts: transforming clinical samples into mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Dissemination and growth of cancer cells in metastatic sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Metastatic colonization by circulating tumour cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

A perspective on cancer cell metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Comparative lesion sequencing provides insights into tumor evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Inflammation and colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Immunity, Inflammation, and Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Molecular and genetic properties of tumors associated with local immune cytolytic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Neoantigens in cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Classification of current anticancer immunotherapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The Basis of Oncoimmunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

T cell exclusion, immune privilege, and the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The blockade of immune checkpoints in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Immune checkpoint blockade: a common denominator approach to cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Immune evasion of microsatellite unstable colorectal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Combining immunotherapy and targeted therapies in cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

Comprehensive molecular characterization of human colon and rectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2016.08.001

10.1016/J.TRECAN.2016.08.001

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28741478%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference